Decreased levels of serum brain,derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders

摘要

Objectives: Brain,derived neurotrophic factor (BDNF) has been proposed as a candidate molecule in the pathophysiology of major depressive disorder (MDD) and bipolar disorders (BD). Reduced levels of peripheral BDNF have been found in drug,free MDD patients, in drug, treated depressed or manic patients with BD type I (BD,I), but not in drug, treated euthymic BD,I individuals. No study has been done in patients with BD type II (BD,II). Moreover, the influence of Axis I psychiatric comorbidity on circulating BDNF in affective patients has never been evaluated. Therefore, in the present study, we aimed: (i) to confirm previous findings on peripheral BDNF in MDD and BD,I patients; (ii) to assess whether changes in circulating BDNF occur also in patients with BD,II; and (iii) to exclude the possibility that comorbid psychiatric disorders exerted an effect on BDNF levels in affective patients.Methods: We measured serum BDNF concentrations by an enzyme, linked immunosorbent assay method in 85 subjects, including 24 euthymic patients with unipolar depression (UD), 17 euthymic patients with BD,I, 11 euthymic patients with BD,II, 11 UD patients with a current major depressive episode and 22 drug,free healthy controls. At the time of the study, 15 patients were drug,treated; the remaining ones were drug,free for at least four weeks.Results: Compared to healthy controls, serum BDNF concentrations were significantly reduced in all the patient groups (F480 = 3.840, p = 0.006) with no significant difference among them. Drug treatments and comorbid psychiatric disorders had no effect on lowered circulating BDNF levels in affective patients.Conclusions: Present results confirm previous independent findings of reduced circulating BDNF in patients with MDD and report, for the first time, decreased serum BDNF levels in euthymic patients with UD, BD,I and BD,II, independently from drug treatment status and concomitant Axis I psychiatric disorders.